Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2021-07-13 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES DOSING OF THE FIRST COHORT OF HEALTHY SUBJECTS IN THE FXR AGONIST ASC42 BRIDGING STUDY FOR CHRONIC HEPATITIS B INDICATION IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the dosing of the first cohort of healthy subjects in a clinical bridging study for a drug candidate (ASC42) for chronic hepatitis B indication in China. It includes details about the study design, prior approvals, and clinical trial identifiers. There are no financial statements, earnings data, or regulatory filings related to financial performance. The document is an announcement of a clinical trial milestone rather than a financial report or regulatory filing. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under a general regulatory announcement category related to company developments but not fitting other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-07-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2021
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 30/6/2021. The content focuses on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting share capital movements and related securities information, typical of a capital/financing update or a regulatory filing. Given the detailed nature of share capital movements and securities issuance, it aligns best with Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains substantive data, not just an announcement or certification, so it is not RPA or RNS. Therefore, the classification is CAP with high confidence.
2021-07-07 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 30 June 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/06/2021, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content is focused on changes in the company's share capital structure during a specific month. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is a regulatory filing reporting share capital movements, typical for compliance with exchange rules. It is not an announcement of a report, nor a full financial report or presentation. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement about share capital movements that does not fit other more specific categories.
2021-07-02 English
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Ascletis Pharma Inc. regarding the grant of share options to participants under the company's share option scheme. It includes details such as the date of grant, number of shares, exercise price, and validity period. The document is relatively short (2725 characters) and is clearly an announcement of a share option grant, which relates to changes in the company's capital structure through share options. It is not a full financial report, audit, or management discussion, nor is it a regulatory certification or voting result. The content fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes such as share options.
2021-06-30 English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 29, 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on June 29, 2021. It details the voting outcomes on various resolutions including receiving the audited financial statements, re-election of directors, appointment of auditors, and share issuance mandates. The document does not contain the full AGM materials or presentations but reports the official voting results. The document length is 4197 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-06-29 English
POLL RESULTS OF ANNUAL GENERAL MEETING ON 25 JUNE 2021
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on 25 June 2021. It details the voting outcomes on various resolutions including adoption of financial statements, re-election of directors, re-appointment of auditors, and granting mandates to directors. The document is relatively short (3710 characters) and focuses on the voting results rather than the full AGM materials or presentations. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'.
2021-06-25 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.